Moreover, high numbers of TNFRSF9–expressing Tregs were associated with poor survival outcomes across multiple human cancers53, consistent with our findings that serum TNFRSF9 associates with lethal prostate cancer. This evidence concerns the gene TNFRSF9 and prostate carcinoma.